Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate-resistance and novel therapeutic approaches
By Theodoros Karantanos, P. Corn, T. Thompson. Oncogene, 2013
797 citations recorded by the source corpus.
Prostate cancer is the second-leading cause of cancer-related mortality in men in Western societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance, defined as disease progression despite serum testosterone levels of <20 ng/dl. The recent discovery that AR signaling persists during systemic castration via intratumoral production of androgens led to the development of novel anti-androgen therapies including abiraterone acetate and enzalutamide. Although these agents effectively palliate symptoms and prolong life, metastatic castration-resistant prostate cancer remains incurable. An increased understanding of the mechanisms that underlie the pathogenesis of castrate resistance is therefore needed to develop novel therapeutic approaches for this disease. The aim of this review is to summarize the current literature on the biology and treatment of castrate-resistant prostate cancer.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/9d6351786bdb01817d052bf544786eb8261b133d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Pulmonary and Respiratory Medicine
Citations in the corpus
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer (2016, background): “Although CRPC is now known to be reliant on androgen signaling, traditional endocrine therapies are ineffective against it (6).”
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. (2018, positive): “This finding suggests that DNA copy gain affecting this locus, commonly by tandem duplication, may be a frequent mechanism by which prostate tumor cells initially develop ADT resistance (Karantanos et al., 2013).”